Study S000484

A Randomised, Open-label, Single-centre, Two-period, Cross-over Trial Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors

ClinicalTrials.gov record

Registration

Registration: NCT02207348
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 24
Start: 2014-08
Primary completion: 2014-09
Lead sponsor: Novo Nordisk A/S
Conditions: Metabolism and Nutrition Disorder; Obesity
Interventions: DRUG:liraglutide
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2014-000216-34; OTHER:U1111-1152-1391; NIH:2014

Registered primary outcomes

Area under the liraglutide plasma concentration time curve from 0 to last quantifiable observation (tz) after single dose [0-72 hours following administration of 0.6 mg liraglutide]
Maximum observed liraglutide plasma concentration after single dose [0-72 hours following administration of 0.6 mg liraglutide]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.